title: Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: results of a phase II study.
abstract: OBJECTIVE
  To evaluate the efficacy and toxicity of ifosfamide and cisplatin administered concomitantly with low-dose-rate brachytherapy followed by consolidation chemotherapy in the treatment of locally advanced squamous cell cervical carcinoma (LASCC).
  
  
  METHODS
  Forty-four patients with biopsy-proven LASCC were enrolled. FIGO Stages IB2 bulky to IVA were entered into this study. Patients were assigned to receive external radiotherapy (50 Gy in 25 fractions); then ifosfamide 2 g/m(2) plus cisplatin 75 mg/m(2) was applied during two low-dose-rate brachytherapy applications, and 4 cycles of consolidation chemotherapy with the same drug combination were given after completion of radiotherapy. The planned dose to point A was 85 Gy.
  
  
  RESULTS
  All patients received both courses of concomitant chemobrachytherapy and at least 1 cycle of consolidation chemotherapy. The average duration of radiation was 45.1 days. The clinical complete response rate was 100%. Grade 3 and 4 leukopenia occurred in 25% and 11% of the cycles, respectively. After a median follow-up of 34 months (range, 20-54 months), the recurrence-free and the overall survival rates were 84% and 91%, respectively. Major delayed local complications occurred in 7 cases (16%).
  
  
  CONCLUSIONS
  These results indicate that concomitant chemobrachyradiotherapy with ifosfamide and cisplatin is a feasible combination for patients with LASCC of the cervix uteri. A randomized trial is planned.
authors.affiliation: Center of Oncology, Clinical Hospital Split, Spinciceva 1, 21000 Split, Croatia. eduard.vrdoljak@st.hinet.hr
authors.forename: Eduard
authors.initials: E
authors.lastname: Vrdoljak
authors.forename: Tomislav
authors.initials: T
authors.lastname: Prskalo
authors.forename: Tomislav
authors.initials: T
authors.lastname: Omrcen
authors.forename: Kristina
authors.initials: K
authors.lastname: Situm
authors.forename: Tihana
authors.initials: T
authors.lastname: Boraska
authors.forename: Nives
authors.initials: N
authors.lastname: Frleta Ilić
authors.forename: Stjepan
authors.initials: S
authors.lastname: Janković
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Hamm
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001918:Brachytherapy / Q000379:methods*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008875:Middle Aged; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*
chemical_list: D011838:Radiation-Sensitizing Agents; D002945:Cisplatin; D007069:Ifosfamide